NCT04027946 2024-04-16
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
Clinical Trials
5 trialsNCT04840615 2024-02-02
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT05375825 2024-02-02
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT03644550 2021-12-02
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03436732 2019-11-22
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated